Johns Hopkins ABX Guide
Darunavir
INDICATIONS
FDA
FDA
- HIV-infected patients who are treatment-experienced and have at least one DRV resistance mutation, in combination with other antiretrovirals (DRV/r 600/100 mg twice daily).
- HIV-infected patients who are treatment-naive (DRV/r 800/100 mg once daily or DRV/c 800/150 mg once daily).
- HIV-infected children (>3 years)
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: November 7, 2020
Citation
Bernice, Fidelia. "Darunavir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2020. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540156/all/Darunavir.
Bernice F. Darunavir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540156/all/Darunavir. Accessed December 3, 2024.
Bernice, F. (2020). Darunavir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540156/all/Darunavir
Bernice F. Darunavir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. [cited 2024 December 03]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540156/all/Darunavir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Darunavir
ID - 540156
A1 - Bernice,Fidelia,Pharm.D., BCIDP
Y1 - 2020/11/07/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540156/all/Darunavir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
